Savara

118 articles with Savara

• Savara Announces New Employment Inducement Grant - January 20, 2023

  1/20/2023

  Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.

• Savara Announces New Employment Inducement Grant

  11/22/2022

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the grant of an employee inducement award.

• Savara Reports Third Quarter 2022 Financial Results and Provides Business Update

  11/10/2022

  Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2022 and provided a business update.

• Savara to Participate in Three Upcoming November 2022 Investor Conferences

  11/9/2022

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will participate at the following investor healthcare conferences.

• Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - September 14, 2022

  9/14/2022

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the grant of inducement awards to three new employees.

• Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022

  9/6/2022

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented three posters at the ERS International Congress 2022 that took place September 4-6th in Barcelona, Spain.

• Savara to Present at H.C. Wainwright 24th Annual Global Investment Conference

  9/1/2022

  Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Matt Pauls, Chair and CEO, Savara will present at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022.

• Savara Announces Resignation of Chief Medical Officer

  8/26/2022

  Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Badrul Chowdhury, M.D., Ph.D., has resigned from his role as Chief Medical Officer, effective September 9, 2022.

• Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

  8/25/2022

  Savara Inc. today announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) granted Promising Innovative Medicine (PIM) designation to molgramostim for the treatment of aPAP, a rare lung disease with no approved pharmaceutical treatments.

• Savara Reports Second Quarter 2022 Financial Results and Provides Business Update

  8/11/2022

  Pivotal Phase 3 IMPALA-2 Trial of Novel Inhaled Biologic, Molgramostim Nebulizer Solution, in Autoimmune Pulmonary Alveolar Proteinosis Remains On-Track IMPALA-2 Top Line Data Expected at the End of 2Q 2024 Company Ends Quarter with ~$142M – Believes it is Sufficiently Capitalized Through 2025

• Savara Announces Acceptance of Three Abstracts at the European Respiratory Society (ERS) International Congress 2022

  7/11/2022

  Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of three abstracts for poster presentation at the ERS International Congress 2022 to be held in-person and virtually, September 4-6, 2022 in Barcelona, Spain.

• Savara Awarded Innovation Passport in United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim), a Novel Investigational Inhaled Biologic

  6/16/2022

  Innovation Passport Awarded to Molgramostim for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP), a Rare Lung Disease.

• Savara to Present at Jefferies Healthcare Conference - June 01, 2022

  6/1/2022

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will present at the Jefferies Healthcare Conference on June 8, 2022 at 1:00 pm ET in New York City.

• Savara to Present at H.C. Wainwright Global Investment Conference

  5/17/2022

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will present at the H.C. Wainwright Global Investment Conference on May 24, 2022 at 4:00 pm ET.

• Savara Reports First Quarter 2022 Financial Results and Provides Business Update

  5/11/2022

  Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2022 and provided a business update.

• Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Apr 26, 2022

  4/26/2022

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the grant of inducement awards to two new employees.

• Savara Announces Debt Refinancing of $26.5M Credit Facility With Silicon Valley Bank

  4/22/2022

  Savara Inc. today announced that it entered into a term loan agreement of $26.5 million with Silicon Valley Bank to replace its existing credit facility with the bank.

• Savara Reports Fourth Quarter / Year-End 2021 Financial Results and Provides Business Update

  3/30/2022

  Savara Inc., an orphan lung disease company, reported financial results for the fourth quarter and full year ending December 31, 2021 and provided a business update.

• Savara to Present at Oppenheimer’s 32nd Annual Healthcare Conference

  3/9/2022

  Savara to Present at Oppenheimer’s 32nd Annual Healthcare Conference.

• Savara to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

  1/4/2022

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will present at the H.C. Wainwright BIOCONNECT Virtual Conference being held January 10-13, 2022.